Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Aug;115(7):1231–1234. doi: 10.1111/j.1476-5381.1995.tb15030.x

An EP receptor with a novel pharmacological profile in the T-cell line Jurkat.

G W De Vries 1, P Guarino 1, A McLaughlin 1, J Chen 1, S Andrews 1, D F Woodward 1
PMCID: PMC1908800  PMID: 7582550

Abstract

1. Comparison of the rank order of potency of the natural prostanoids prostaglandin E2 (PGE2), PGD2, PGF2 alpha and carbaprostacyclin in stimulating cyclic AMP in Jurkat cells is consistent with the presence of an EP receptor. 2. Lack of responsiveness to the EP1/EP3 selective agonist, sulprostone, and the EP2 agonists, butaprost and AH 13205, indicates that this receptor is not of the EP1, EP2 or EP3 subtypes. 3. Inhibition of PGE2-stimulated cyclic AMP by the EP4 antagonist, AH 23848 is non-competitive, unlike the competitive antagonism reported in the pig saphenous vein EP4 preparation. Furthermore, 16,16-dimethyl PGE2 is 100 fold less potent than PGE2 in Jurkat cells, while these agonists are equipotent in the rabbit jugular vein purported EP4 preparation. In addition, 1-OH PGE1, which also is active in the rabbit jugular vein preparation, is inactive in Jurkat cells at concentrations up to 1 x 10(-4) M. These data are not wholly consistent with any adenylate cyclase coupled EP receptor described to date. 4. It is postulated that an EP receptor, positively coupled to adenylate cyclase, with a unique pharmacological profile is present in Jurkat cells.

Full text

PDF
1234

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastassiou E. D., Paliogianni F., Balow J. P., Yamada H., Boumpas D. T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol. 1992 May 1;148(9):2845–2852. [PubMed] [Google Scholar]
  2. Anderson C. B., Jaffee B. M., Graff R. J. Prolongation of murine skin allografts by prostaglandin E1. Transplantation. 1977 May;23(5):444–447. doi: 10.1097/00007890-197705000-00010. [DOI] [PubMed] [Google Scholar]
  3. Bastin B., Payet M. D., Dupuis G. Effects of modulators of adenylyl cyclase on interleukin-2 production, cytosolic Ca2+ elevation, and K+ channel activity in Jurkat T cells. Cell Immunol. 1990 Jul;128(2):385–389. doi: 10.1016/0008-8749(90)90035-p. [DOI] [PubMed] [Google Scholar]
  4. Betz M., Fox B. S. Prostaglandin E2 inhibits production of Th1 lymphokines but not of Th2 lymphokines. J Immunol. 1991 Jan 1;146(1):108–113. [PubMed] [Google Scholar]
  5. Chen J., Woodward D. F. Prostanoid-induced relaxation of precontracted cat ciliary muscle is mediated by EP2 and DP receptors. Invest Ophthalmol Vis Sci. 1992 Oct;33(11):3195–3201. [PubMed] [Google Scholar]
  6. Coleman R. A., Grix S. P., Head S. A., Louttit J. B., Mallett A., Sheldrick R. L. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins. 1994 Feb;47(2):151–168. doi: 10.1016/0090-6980(94)90084-1. [DOI] [PubMed] [Google Scholar]
  7. Coleman R. A., Smith W. L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205–229. [PubMed] [Google Scholar]
  8. Elliott L., Brooks W., Roszman T. Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination. Cell Mol Neurobiol. 1992 Oct;12(5):411–427. doi: 10.1007/BF00711542. [DOI] [PubMed] [Google Scholar]
  9. Eriksen E. F., Richelsen B., Beck-Nielsen H., Melsen F., Nielsen H. K., Mosekilde L. Prostaglandin E2 receptors on human peripheral blood monocytes. Scand J Immunol. 1985 Feb;21(2):167–172. doi: 10.1111/j.1365-3083.1985.tb01416.x. [DOI] [PubMed] [Google Scholar]
  10. Gardiner P. J. Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979. Br J Pharmacol. 1986 Jan;87(1):45–56. doi: 10.1111/j.1476-5381.1986.tb10155.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goodwin J. S., Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983 Oct;3(4):295–315. doi: 10.1007/BF00915791. [DOI] [PubMed] [Google Scholar]
  12. Goodwin J. S., Wiik A., Lewis M., Bankhurst A. D., Williams R. C., Jr High-affinity binding sites for prostaglandin E on human lymphocytes. Cell Immunol. 1979 Mar 1;43(1):150–159. doi: 10.1016/0008-8749(79)90158-8. [DOI] [PubMed] [Google Scholar]
  13. Harper J. F., Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1975;1(4):207–218. [PubMed] [Google Scholar]
  14. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  15. Krause D. S., Deutsch C. Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected. J Immunol. 1991 Apr 1;146(7):2285–2296. [PubMed] [Google Scholar]
  16. Lawrence R. A., Jones R. L. Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol. 1992 Apr;105(4):817–824. doi: 10.1111/j.1476-5381.1992.tb09063.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lawrence R. A., Jones R. L., Wilson N. H. Characterization of receptors involved in the direct and indirect actions of prostaglandins E and I on the guinea-pig ileum. Br J Pharmacol. 1992 Feb;105(2):271–278. doi: 10.1111/j.1476-5381.1992.tb14245.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lingk D. S., Chan M. A., Gelfand E. W. Increased cyclic adenosine monophosphate levels block progression but not initiation of human T cell proliferation. J Immunol. 1990 Jul 15;145(2):449–455. [PubMed] [Google Scholar]
  19. Mary D., Aussel C., Ferrua B., Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol. 1987 Aug 15;139(4):1179–1184. [PubMed] [Google Scholar]
  20. Minakuchi R., Wacholtz M. C., Davis L. S., Lipsky P. E. Delineation of the mechanism of inhibition of human T cell activation by PGE2. J Immunol. 1990 Oct 15;145(8):2616–2625. [PubMed] [Google Scholar]
  21. Namba T., Sugimoto Y., Negishi M., Irie A., Ushikubi F., Kakizuka A., Ito S., Ichikawa A., Narumiya S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature. 1993 Sep 9;365(6442):166–170. doi: 10.1038/365166a0. [DOI] [PubMed] [Google Scholar]
  22. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  23. Plaut M. Lymphocyte hormone receptors. Annu Rev Immunol. 1987;5:621–669. doi: 10.1146/annurev.iy.05.040187.003201. [DOI] [PubMed] [Google Scholar]
  24. Rincón M., Tugores A., López-Rivas A., Silva A., Alonso M., De Landázuri M. O., López-Botet M. Prostaglandin E2 and the increase of intracellular cAMP inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol. 1988 Nov;18(11):1791–1796. doi: 10.1002/eji.1830181121. [DOI] [PubMed] [Google Scholar]
  25. Skålhegg B. S., Taskén K., Hansson V., Huitfeldt H. S., Jahnsen T., Lea T. Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science. 1994 Jan 7;263(5143):84–87. doi: 10.1126/science.8272870. [DOI] [PubMed] [Google Scholar]
  26. Smith G. C., Coleman R. A., McGrath J. C. Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus. J Pharmacol Exp Ther. 1994 Oct;271(1):390–396. [PubMed] [Google Scholar]
  27. Strom T. B., Carpenter C. B., Jr, Cragoe E. J., Jr, Norris S., Devlin R., Perper R. J. Suppression of in vivo and in vitro alloimmunity by prostaglandins. Transplant Proc. 1977 Mar;9(1):1075–1079. [PubMed] [Google Scholar]
  28. Wacholtz M. C., Minakuchi R., Lipsky P. E. Characterization of the 3',5'-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells. Cell Immunol. 1991 Jul;135(2):285–298. doi: 10.1016/0008-8749(91)90274-f. [DOI] [PubMed] [Google Scholar]
  29. Walker C., Kristensen F., Bettens F., deWeck A. L. Lymphokine regulation of activated (G1) lymphocytes. I. Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol. 1983 Apr;130(4):1770–1773. [PubMed] [Google Scholar]
  30. Whittum J., Goldschneider I., Greiner D., Zurier R. Developmental abnormalities of terminal deoxynucleotidyl transferase positive bone marrow cells and thymocytes in New Zealand mice: effects of prostaglandin E1. J Immunol. 1985 Jul;135(1):272–280. [PubMed] [Google Scholar]
  31. Williams T. L., Smith D. A., Burton N. R., Stone T. W. Amino acid pharmacology in neocortical slices: evidence for bimolecular actions from an extension of the Hill and Gaddum-Schild equations. Br J Pharmacol. 1988 Nov;95(3):805–810. doi: 10.1111/j.1476-5381.1988.tb11708.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Woodward D. F., Protzman C. E., Krauss A. H., Williams L. S. Identification of 19 (R)-OH prostaglandin E2 as a selective prostanoid EP2-receptor agonist. Prostaglandins. 1993 Oct;46(4):371–383. doi: 10.1016/0090-6980(93)90102-d. [DOI] [PubMed] [Google Scholar]
  33. Zurier R. B., Quagliata F. Effect of prostaglandin E 1 on adjuvant arthritis. Nature. 1971 Dec 3;234(5327):304–305. doi: 10.1038/234304a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES